This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Advanced Cell Technology Announces Fourth-Quarter And Year-end Results

Advanced Cell Technology, Inc. (“ACT”, OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, today announced fourth quarter and year-end financial results for the period ended December 31, 2012.

Highlights from the fourth quarter included:

  • Completed second patient cohort in all three clinical trials in the U.S. and Europe to treat Stargardt’s Macular Dystrophy (SMD) and dry Age Related Macular Degeneration (AMD), effectively reaching the halfway point of all three groundbreaking clinical trials.
  • Received Data Safety and Monitoring Board (DSMB) approval to treat the second patient cohorts in the U.S. and European clinical trials for SMD and dry AMD and commenced enrollment and treatment of patients in the trial with the higher dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells.
  • In addition to reporting that all 18 patients across the three trials have been treated and no safety issues had arisen( the primary purpose behind the Phase I studies is to assess safety), the Company also released positive interim data citing the integration of the RPE cells in the proper anatomical site in the eye and noted visual acuity improvements from the patients.
  • ACT’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet program chosen by New Scientist Magazine as one of “10 ideas that will shape the year.”

“2012 represented a transformative year for ACT both clinically and through favorable corporate developments,” said Gary Rabin, chairman and CEO of ACT. “The Company announced promising data from its most advanced clinical programs in AMD and SMD, and has made solid progress in bringing each of these programs through the clinical trials. ACT has also been able to remove many of the impediments to achieving a listing of its stock on a National Exchange, by eliminating significant contingent liabilities through resolution of outstanding litigation. We believe the Company is now well positioned to achieve both its clinical and corporate objectives in 2013.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,919.59 +80.85 0.48%
S&P 500 1,981.60 +9.86 0.50%
NASDAQ 4,527.5140 +19.2020 0.43%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs